ES2197330T3 - Metodo para detectar el virus de gripe y compuestos para emplear en el. - Google Patents

Metodo para detectar el virus de gripe y compuestos para emplear en el.

Info

Publication number: ES2197330T3
Authority: ES; Spain
Prior art keywords: group; neuraminidase; binder; compound; virus
Prior art date: 1996-03-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES97903154T

Other languages

English (en)

Spanish (es)

Inventor

Philip A. Reece

Wen-Yang Wu

Betty Jin

Guy Y. Krippner

Keith Geoffrey Watson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Biota Scientific Management Pty Ltd

Original Assignee

Biota Scientific Management Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-01

Filing date

1997-02-26

Publication date

2004-01-01

1996-03-01 Priority claimed from AUPN8397A external-priority patent/AUPN839796A0/en

1996-09-04 Priority claimed from AUPO2131A external-priority patent/AUPO213196A0/en

1996-11-14 Priority claimed from AUPO3631A external-priority patent/AUPO363196A0/en

1997-02-26 Application filed by Biota Scientific Management Pty Ltd filed Critical Biota Scientific Management Pty Ltd

2004-01-01 Application granted granted Critical

2004-01-01 Publication of ES2197330T3 publication Critical patent/ES2197330T3/es

2017-02-26 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 125
238000000034 method Methods 0.000 title claims abstract description 69
241000700605 Viruses Species 0.000 title claims abstract description 59
102000005348 Neuraminidase Human genes 0.000 claims abstract description 78
108010006232 Neuraminidase Proteins 0.000 claims abstract description 78
238000001514 detection method Methods 0.000 claims abstract description 34
239000011230 binding agent Substances 0.000 claims description 53
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 48
239000000203 mixture Substances 0.000 claims description 32
206010022000 influenza Diseases 0.000 claims description 27
125000006850 spacer group Chemical group 0.000 claims description 26
241000712461 unidentified influenza virus Species 0.000 claims description 22
239000002253 acid Substances 0.000 claims description 19
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 18
229960002685 biotin Drugs 0.000 claims description 17
239000011616 biotin Substances 0.000 claims description 17
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 17
238000006243 chemical reaction Methods 0.000 claims description 16
239000002245 particle Substances 0.000 claims description 16
239000003550 marker Substances 0.000 claims description 15
229910052760 oxygen Inorganic materials 0.000 claims description 12
235000020958 biotin Nutrition 0.000 claims description 10
230000003612 virological effect Effects 0.000 claims description 10
125000000217 alkyl group Chemical group 0.000 claims description 8
-1 amino, hydroxy Chemical group 0.000 claims description 8
238000004458 analytical method Methods 0.000 claims description 8
125000004429 atom Chemical group 0.000 claims description 7
238000003745 diagnosis Methods 0.000 claims description 7
108090001008 Avidin Proteins 0.000 claims description 6
125000003277 amino group Chemical group 0.000 claims description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
150000002148 esters Chemical class 0.000 claims description 6
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 6
239000001301 oxygen Substances 0.000 claims description 6
125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims description 5
150000002430 hydrocarbons Chemical class 0.000 claims description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
125000003118 aryl group Chemical group 0.000 claims description 4
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 4
BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical class OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical class CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 4
125000005629 sialic acid group Chemical group 0.000 claims description 4
125000001424 substituent group Chemical group 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
230000004520 agglutination Effects 0.000 claims description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
230000008878 coupling Effects 0.000 claims description 3
238000010168 coupling process Methods 0.000 claims description 3
238000005859 coupling reaction Methods 0.000 claims description 3
229930195733 hydrocarbon Natural products 0.000 claims description 3
239000000463 material Substances 0.000 claims description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
230000003287 optical effect Effects 0.000 claims description 3
NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 claims description 3
230000001012 protector Effects 0.000 claims description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
239000004215 Carbon black (E152) Substances 0.000 claims description 2
239000002202 Polyethylene glycol Substances 0.000 claims description 2
108010090804 Streptavidin Proteins 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
150000001263 acyl chlorides Chemical class 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
125000003368 amide group Chemical group 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims description 2
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims description 2
150000004657 carbamic acid derivatives Chemical class 0.000 claims description 2
239000004202 carbamide Substances 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
229910002091 carbon monoxide Inorganic materials 0.000 claims description 2
239000012141 concentrate Substances 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
125000003827 glycol group Chemical group 0.000 claims description 2
125000004438 haloalkoxy group Chemical group 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 claims description 2
239000012038 nucleophile Substances 0.000 claims description 2
229920001542 oligosaccharide Polymers 0.000 claims description 2
150000002482 oligosaccharides Chemical class 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
229920001223 polyethylene glycol Polymers 0.000 claims description 2
229920005862 polyol Polymers 0.000 claims description 2
150000003077 polyols Chemical class 0.000 claims description 2
108090000765 processed proteins & peptides Proteins 0.000 claims description 2
102000004196 processed proteins & peptides Human genes 0.000 claims description 2
230000000717 retained effect Effects 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
125000004434 sulfur atom Chemical group 0.000 claims description 2
238000003786 synthesis reaction Methods 0.000 claims description 2
230000001681 protective effect Effects 0.000 claims 2
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims 1
230000002378 acidificating effect Effects 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 claims 1
125000001183 hydrocarbyl group Chemical group 0.000 claims 1
230000002194 synthesizing effect Effects 0.000 claims 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 50
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 45
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
238000002360 preparation method Methods 0.000 description 30
239000000243 solution Substances 0.000 description 26
229910052786 argon Inorganic materials 0.000 description 25
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
239000007787 solid Substances 0.000 description 19
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 18
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
239000006260 foam Substances 0.000 description 13
208000037797 influenza A Diseases 0.000 description 13
239000000741 silica gel Substances 0.000 description 13
229910002027 silica gel Inorganic materials 0.000 description 13
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
238000012360 testing method Methods 0.000 description 10
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
238000004587 chromatography analysis Methods 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
238000002965 ELISA Methods 0.000 description 7
239000011541 reaction mixture Substances 0.000 description 7
229920005989 resin Polymers 0.000 description 7
239000011347 resin Substances 0.000 description 7
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
238000003818 flash chromatography Methods 0.000 description 6
208000037798 influenza B Diseases 0.000 description 6
239000012528 membrane Substances 0.000 description 6
102200126728 rs587777863 Human genes 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
241000712431 Influenza A virus Species 0.000 description 3
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
238000013459 approach Methods 0.000 description 3
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
229940126656 GS-4224 Drugs 0.000 description 2
241000713196 Influenza B virus Species 0.000 description 2
JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
238000011953 bioanalysis Methods 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
229920001429 chelating resin Polymers 0.000 description 2
239000003593 chromogenic compound Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
239000000185 hemagglutinin Substances 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
235000019799 monosodium phosphate Nutrition 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
238000005406 washing Methods 0.000 description 2
NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
LNROBGCNCFXALJ-XXPVTVGNSA-N 2-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]dodecanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NC(CCCCCCCCCC)C(O)=O)SC[C@@H]21 LNROBGCNCFXALJ-XXPVTVGNSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
BIZULEWPNGZPNN-WBGPXRNDSA-N C(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12)(=O)NC(C(=O)O)CCCC Chemical compound C(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12)(=O)NC(C(=O)O)CCCC BIZULEWPNGZPNN-WBGPXRNDSA-N 0.000 description 1
QXGKSHGCXPONGA-UHFFFAOYSA-N CC(C)(C)OC(=O)C(N)CCCCC(=O)C(N)(N)CCCCC(=O)CCCCC(N)C(O)=O Chemical compound CC(C)(C)OC(=O)C(N)CCCCC(=O)C(N)(N)CCCCC(=O)CCCCC(N)C(O)=O QXGKSHGCXPONGA-UHFFFAOYSA-N 0.000 description 1
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
238000006751 Mitsunobu reaction Methods 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
239000000980 acid dye Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000007605 air drying Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
239000012568 clinical material Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000012364 cultivation method Methods 0.000 description 1
150000005676 cyclic carbonates Chemical class 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000000596 cyclohexenyl group Chemical class C1(=CCCCC1)* 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
230000014670 detection of bacterium Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000000975 dye Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
102000013361 fetuin Human genes 0.000 description 1
108060002885 fetuin Proteins 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
238000009533 lab test Methods 0.000 description 1
238000003771 laboratory diagnosis Methods 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical compound [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
UCQFSGCWHRTMGG-UHFFFAOYSA-N pyrazole-1-carboximidamide Chemical compound NC(=N)N1C=CC=N1 UCQFSGCWHRTMGG-UHFFFAOYSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
RVZPDKXEHIRFPM-UHFFFAOYSA-N tert-butyl n-(6-aminohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCN RVZPDKXEHIRFPM-UHFFFAOYSA-N 0.000 description 1
OCUICOFGFQENAS-UHFFFAOYSA-N tert-butyl n-[2-[2-(2-aminoethoxy)ethoxy]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOCCOCCN OCUICOFGFQENAS-UHFFFAOYSA-N 0.000 description 1
QFNFDHNZVTWZED-UHFFFAOYSA-N tert-butyl n-[[(2-methylpropan-2-yl)oxycarbonylamino]-pyrazol-1-ylmethylidene]carbamate Chemical compound CC(C)(C)OC(=O)NC(=NC(=O)OC(C)(C)C)N1C=CC=N1 QFNFDHNZVTWZED-UHFFFAOYSA-N 0.000 description 1
238000011282 treatment Methods 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Analytical Chemistry (AREA)
General Health & Medical Sciences (AREA)
Cell Biology (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Apparatus For Disinfection Or Sterilisation (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

ES97903154T 1996-03-01 1997-02-26 Metodo para detectar el virus de gripe y compuestos para emplear en el. Expired - Lifetime ES2197330T3 (es)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
AUPN8397A AUPN839796A0 (en)	1996-03-01	1996-03-01	Method and novel compounds for use therein
AUPN839796		1996-03-01
AUPO213196		1996-09-04
AUPO2131A AUPO213196A0 (en)	1996-09-04	1996-09-04	Method and novel compounds for use therein
AUPO363196		1996-11-14
AUPO3631A AUPO363196A0 (en)	1996-11-14	1996-11-14	Method and novel compounds for use therein

Publications (1)

Publication Number	Publication Date
ES2197330T3 true ES2197330T3 (es)	2004-01-01

Family

ID=27157905

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES97903154T Expired - Lifetime ES2197330T3 (es)	1996-03-01	1997-02-26	Metodo para detectar el virus de gripe y compuestos para emplear en el.

Country Status (13)

Country	Link
US (2)	US6242582B1 (2)
EP (1)	EP0885391B1 (2)
JP (1)	JP3753740B2 (2)
KR (1)	KR19990087449A (2)
AT (1)	ATE238552T1 (2)
CA (1)	CA2245680C (2)
DE (1)	DE69721242T2 (2)
ES (1)	ES2197330T3 (2)
HU (1)	HU223099B1 (2)
IL (1)	IL125662A0 (2)
NO (1)	NO326042B1 (2)
NZ (1)	NZ331189A (2)
WO (1)	WO1997032214A1 (2)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1215390A (zh) *	1996-04-02	1999-04-28	拜尔公司	取代的苯基酮烯醇杀虫剂及除草剂
JP3209946B2 (ja)	1996-07-22	2001-09-17	三共株式会社	ノイラミン酸誘導体
NZ335368A (en) *	1996-11-14	2001-08-31	Biota Scient Management	Macromolecular compound with one or more neuraminidase binders, binds to the active site of influenza virus neuraminidase
AU1927899A (en) *	1997-12-18	1999-07-05	Sepracor, Inc.	Screening assays for the detection and diagnosis of influenza virus
JP3233392B2 (ja)	1998-01-22	2001-11-26	三共株式会社	ノイラミン酸誘導体を含有する抗インフルエンザ薬
US6455571B1 (en)	1998-04-23	2002-09-24	Abbott Laboratories	Inhibitors of neuraminidases
US6518305B1 (en)	1998-04-23	2003-02-11	Abbott Laboratories	Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases
WO2000028328A1 (en) *	1998-11-05	2000-05-18	Biocryst Pharmaceuticals, Inc.	New cyclopentane and cyclopentene compounds and use for detecting influenza virus
AUPP913999A0 (en)	1999-03-12	1999-04-01	Biota Scientific Management Pty Ltd	Novel chemical compounds and their use
US6593314B1 (en)	1999-10-19	2003-07-15	Abbott Laboratories	Neuraminidase inhibitors
US6627396B1 (en) *	1999-10-28	2003-09-30	The Regents Of The University Of California	Influenza sensor
AUPR001000A0 (en) *	2000-09-08	2000-10-05	Biota Scientific Management Pty Ltd	Novel chemical compounds and their use
WO2002092555A1 (en) *	2001-05-11	2002-11-21	Sankyo Company, Limited	Sialic acid derivatives
EP1423385B1 (en)	2001-09-07	2008-07-02	Biota Scientific Management Pty. Ltd.	Intermediates for preparing neuraminidase inhibitor conjugates
AUPR879601A0 (en) *	2001-11-09	2001-12-06	Biota Scientific Management Pty Ltd	Novel chemical compounds and their use
AUPR879401A0 (en) *	2001-11-09	2001-12-06	Biota Scientific Management Pty Ltd	Novel chemical compounds and their use
CN1285591C (zh) *	2001-11-09	2006-11-22	百奥塔科学管理有限公司	二聚化合物及其作为抗病毒剂的应用
AUPR879701A0 (en) *	2001-11-09	2001-12-06	Biota Scientific Management Pty Ltd	Novel chemical compounds and their use
AUPR879501A0 (en) *	2001-11-09	2001-12-06	Biota Scientific Management Pty Ltd	Novel chemical compounds and their use
KR101931899B1 (ko)	2005-05-09	2018-12-21	테라노스, 인코포레이티드	현장진료 유체 시스템 및 그 용도
US8741230B2 (en)	2006-03-24	2014-06-03	Theranos, Inc.	Systems and methods of sample processing and fluid control in a fluidic system
US11287421B2 (en)	2006-03-24	2022-03-29	Labrador Diagnostics Llc	Systems and methods of sample processing and fluid control in a fluidic system
US8007999B2 (en) *	2006-05-10	2011-08-30	Theranos, Inc.	Real-time detection of influenza virus
CA2655873C (en)	2006-07-14	2017-10-17	Wisconsin Alumni Research Foundation	Adsorptive membranes for trapping viruses
US8097419B2 (en)	2006-09-12	2012-01-17	Longhorn Vaccines & Diagnostics Llc	Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US20090098527A1 (en) *	2006-09-12	2009-04-16	Fischer Gerald W	Biological organism identification product and methods
US8080645B2 (en)	2007-10-01	2011-12-20	Longhorn Vaccines & Diagnostics Llc	Biological specimen collection/transport compositions and methods
US8652782B2 (en)	2006-09-12	2014-02-18	Longhorn Vaccines & Diagnostics, Llc	Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en)	2006-09-12	2016-11-01	Longhorn Vaccines And Diagnostics, Llc	Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US20080113391A1 (en) *	2006-11-14	2008-05-15	Ian Gibbons	Detection and quantification of analytes in bodily fluids
GB0702183D0 (en) *	2007-02-05	2007-03-14	Iti Scotland Ltd	Pathogen binding
TWI546306B (zh) *	2007-04-11	2016-08-21	第一三共股份有限公司	神經胺酸衍生物之製造方法
US8158430B1 (en)	2007-08-06	2012-04-17	Theranos, Inc.	Systems and methods of fluidic sample processing
US9683256B2 (en)	2007-10-01	2017-06-20	Longhorn Vaccines And Diagnostics, Llc	Biological specimen collection and transport system
US11041215B2 (en)	2007-08-24	2021-06-22	Longhorn Vaccines And Diagnostics, Llc	PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en)	2007-08-27	2018-06-26	Longhorn Vaccines And Diagnostics, Llc	Composite antigenic sequences and vaccines
AU2008293504B2 (en)	2007-08-27	2012-04-12	Longhorn Vaccines & Diagnostics, Llc	Immunogenic compositions and methods
US11041216B2 (en)	2007-10-01	2021-06-22	Longhorn Vaccines And Diagnostics, Llc	Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
CA2861667C (en)	2007-10-01	2017-06-13	Longhorn Vaccines And Diagnostics, Llc	Biological specimen collection and transport system and methods of use
JP5986745B2 (ja)	2008-07-15	2016-09-06	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
CA3081708C (en)	2009-10-19	2023-10-03	Theranos Ip Company, Llc	Integrated health data capture and analysis system
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US10338069B2 (en)	2010-04-12	2019-07-02	Academia Sinica	Glycan arrays for high throughput screening of viruses
CN103068378B (zh) *	2010-05-10	2016-07-06	中央研究院	具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法
WO2013112916A1 (en)	2012-01-26	2013-08-01	Longhorn Vaccines And Diagnostics, Llc	Composite antigenic sequences and vaccines
WO2014031498A1 (en)	2012-08-18	2014-02-27	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
EP2905615B1 (en) *	2012-10-05	2018-11-28	Denka Seiken Co., Ltd.	Method for measuring hemagglutinin from influenza virus
US9782476B2 (en)	2013-09-06	2017-10-10	Academia Sinica	Human iNKT cell activation using glycolipids with altered glycosyl groups
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102512592B1 (ko)	2014-05-27	2023-03-21	아카데미아 시니카	항-ｈｅｒ2 글리코항체 및 이의 용도
CZ2014527A3 (cs) *	2014-08-05	2016-02-17	Ústav Organické Chemie A Biochemie Akademie Věd Čr, V.V.I.	Způsob detekce aktivní formy analytů ve vzorku a stanovení schopnosti dalších látek vázat se do aktivních míst těchto analytů
WO2016183292A1 (en)	2015-05-14	2016-11-17	Longhorn Vaccines And Diagnostics, Llc	Rapid methods for the extraction of nucleic acids from biological samples
WO2017156192A1 (en)	2016-03-08	2017-09-14	Academia Sinica	Methods for modular synthesis of n-glycans and arrays thereof
CN108003065B (zh) *	2016-10-27	2021-01-08	中国石油化工股份有限公司	一种具有增稠作用的化合物和润滑脂以及它们的制备方法
KR102752322B1 (ko)	2023-09-20	2025-01-09	거제대학교산학협력단	단열 기능을 가진 립스틱 용기

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2450877A1 (fr) *	1979-03-06	1980-10-03	Inst Nat Sante Rech Med	Nouveaux tests par agglutination pour la detection des virus de la grippe, et reactifs pour la realisation de ces tests
AU7176091A (en) *	1989-12-29	1991-07-24	Symex Corp.	Chromogenic 7- or 8-position modified n-acetylneuraminic acid substrates and methods for diagnosing human influenza therewith
AU656721B2 (en)	1989-12-29	1995-02-16	Symex Corp.	Methods for diagnosting human influenza and 4-position modified chromogenic N-acetylneuraminic acid substrates for use therein
AU7176191A (en) *	1990-01-05	1991-07-24	Symex Corp.	Chromogenic 5-position modified neuraminic acid substrates and methods for diagnosing human influenza therewith
AU7150891A (en) *	1990-01-10	1991-08-05	Symex Corp.	Chromogenic 9-position modified n-acetylneuraminic acid substrates and methods for diagnosing human influenza therewith
CZ288492B6 (en)	1990-04-24	2001-06-13	Biota Scient Management	Derivatives of alpha-D-neuraminic acid, process of their preparation, their use and pharmaceutical preparations based thereon
WO1992006691A1 (en)	1990-10-19	1992-04-30	Biota Scientific Management Pty. Ltd.	Anti-viral compounds that bind the active site of influenza neuramidase and display in vivo activity against orthomyxovirus and paramyxovirus
DE69131504T2 (de) *	1990-12-31	1999-11-18	Oklahoma Medical Research Foundation, Oklahoma	Verfahren zum visuellen nachweis der anwesenheit eines virus in einer klinischen probe
US5453533A (en) *	1994-04-14	1995-09-26	The University Of Alabama At Birmingham	Inhibitors of influenza virus neuraminidase and methods of making and using the same
GB9516276D0 (en)	1995-08-08	1995-10-11	Biota Scient Management	Chemical compounds
US6204002B1 (en) *	1996-10-22	2001-03-20	Daikin Industries, Ltd.	Gangliosides having fluorescent-tagged ceramide moieties

1997
- 1997-02-26 CA CA002245680A patent/CA2245680C/en not_active Expired - Fee Related
- 1997-02-26 JP JP53046197A patent/JP3753740B2/ja not_active Expired - Fee Related
- 1997-02-26 NZ NZ331189A patent/NZ331189A/xx not_active IP Right Cessation
- 1997-02-26 EP EP97903154A patent/EP0885391B1/en not_active Expired - Lifetime
- 1997-02-26 WO PCT/AU1997/000109 patent/WO1997032214A1/en not_active Ceased
- 1997-02-26 ES ES97903154T patent/ES2197330T3/es not_active Expired - Lifetime
- 1997-02-26 US US09/142,088 patent/US6242582B1/en not_active Expired - Lifetime
- 1997-02-26 DE DE69721242T patent/DE69721242T2/de not_active Expired - Lifetime
- 1997-02-26 HU HU9901679A patent/HU223099B1/hu not_active IP Right Cessation
- 1997-02-26 AT AT97903154T patent/ATE238552T1/de not_active IP Right Cessation
- 1997-02-26 IL IL12566297A patent/IL125662A0/xx unknown
- 1997-02-26 KR KR1019980706873A patent/KR19990087449A/ko not_active Ceased
1998
- 1998-08-31 NO NO19984004A patent/NO326042B1/no not_active IP Right Cessation
2001
- 2001-04-03 US US09/823,766 patent/US20020055094A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO326042B1 (no)	2008-09-08
ATE238552T1 (de)	2003-05-15
IL125662A0 (en)	1999-04-11
JP2000506008A (ja)	2000-05-23
HUP9901679A2 (hu)	1999-09-28
US6242582B1 (en)	2001-06-05
NO984004D0 (no)	1998-08-31
DE69721242T2 (de)	2004-01-29
CA2245680A1 (en)	1997-09-04
HU223099B1 (hu)	2004-03-29
EP0885391A1 (en)	1998-12-23
WO1997032214A1 (en)	1997-09-04
JP3753740B2 (ja)	2006-03-08
US20020055094A1 (en)	2002-05-09
CA2245680C (en)	2005-09-27
EP0885391A4 (en)	2001-07-25
NO984004L (no)	1998-11-02
HUP9901679A3 (en)	2000-06-28
DE69721242D1 (de)	2003-05-28
KR19990087449A (ko)	1999-12-27
NZ331189A (en)	1999-06-29
EP0885391B1 (en)	2003-04-23

Publication	Publication Date	Title
ES2197330T3 (es)	2004-01-01	Metodo para detectar el virus de gripe y compuestos para emplear en el.
AU732916B2 (en)	2001-05-03	Method and novel compounds for use therein
US6503745B1 (en)	2003-01-07	Cyclopentane and cyclopentene compounds and use for detecting influenza virus
ES2313730T3 (es)	2009-03-01	Derivados y analogos del acido 2-desoxi-2,3-deshibro-n-acetilneuraminico y su ulitizacion como agentes antiviricos.
CN102627615B (zh)	2014-01-01	一种化合物l-4-四嗪-苯丙氨酸及其制备方法和应用
IT8149318A1 (it)	1983-03-18	Derivati di l-arginale e metodo per produrli
ES2773056T3 (es)	2020-07-09	Método de detección de formas activas de analito
ES2972588T3 (es)	2024-06-13	Sustrato de glicosidasa fluorogénica y método de detección asociado
Hattori et al.	2016	Solution-phase synthesis and biological evaluation of triostin A and its analogues
Danieli et al.	2007	Molecular probe for enzymatic activity with dual output
CN108484632A (zh)	2018-09-04	青蒿素-苯胺基喹唑啉类衍生物及其制备方法和应用
Li et al.	2003	Cholic acid as template for multivalent peptide assembly
US5359121A (en)	1994-10-25	Glycine derivative monosodium salt tetrahydrate
Konda et al.	2001	First total synthesis of Mer-N5075A and a diastereomeric mixture of α and β-MAPI, new HIV-I protease inhibitors from a species of Streptomyces
Li et al.	2007	Synthesis and anti-HIV activity of trivalent CD4-mimetic miniproteins
Rasmussen et al.	2011	Synthesis of uronic-Noeurostegine–a potent bacterial β-glucuronidase inhibitor
AU706810B2 (en)	1999-06-24	Method of detection of influenza virus and compounds for use therein
CN114249782A (zh)	2022-03-29	一种选择性破坏衰老细胞溶酶体的前药及其制备方法与应用
Singethan et al.	2010	N-(3-Cyanophenyl)-2-phenylacetamide, an effective inhibitor of morbillivirus-induced membrane fusion with low cytotoxicity
KITAGAWA et al.	1976	Studies on Viomycin. IX. Amino Acid Derivatives of Viomycin
CN111153962B (zh)	2021-09-28	一种血栓性血小板减少性紫癜病诊断探针及其制备方法和应用
Muzaffar	2022	Studies Toward Synthesis of a Protected Derivative of L-Enduracididine Via CH Activation
CN115372341A (zh)	2022-11-22	D-赖氨酸衍生物构筑的细菌细胞壁新生肽聚糖的生物发光检测体系及应用方法
JPS62122599A (ja)	1987-06-03	酵素活性測定用ペプチド誘導体及びその使用法
EP0176913A2 (de)	1986-04-09	Neue Glycourethanverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung